Abstract

The Biomedical Advanced Research and Development Authority (BARDA) conducts the advanced research and development and procurement of vaccines, therapeutics, and diagnostics for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. Since its inception in 2006, BARDA has played a critical role in partnering with industry to advance candidates in development towards FDA approval and then procuring them for potential use in a public health emergency. A decade into its existence, we now reflect on how BARDA is improved the preparedness posture of the United States against CBRN threat agents. BARDA has stockpiled or is the process of stockpiling twenty one products for potential use in public health emergencies. Six products have achieved US Food and Drug Administration (FDA) approval or licensure. For several threat agents, the entire repertoire of medical countermeasures that have been procured and stockpiled should serve as a substantial deterrent to their future use in an attack.

You do not currently have access to this article.

Comments

0 Comments